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OBJECTIVE—Vascular endothelial growth factor (VEGF) con-
tributes to diabetic retinopathy, but control of its expression is
not well understood. Here, we tested the hypothesis that hyper-
glycemia mediates induction of VEGF expression in a eukaryotic
initiation factor 4E (eIF4E) binding protein (4E-BP) 1 and 2
dependent manner.
RESEARCH DESIGN AND METHODS—The retina was har-
vested from control and type 1 diabetic rats and mice and
analyzed for VEGF mRNA and protein expression as well as
biomarkers of translational control mechanisms. Similar analy-
ses were performed in Mu ¨ller cell cultures exposed to hypergly-
cemic conditions. The effect of 4E-BP1 and 4E-BP2 gene deletion
on VEGF expression was examined in mice and in mouse embryo
ﬁbroblasts (MEFs).
RESULTS—Whereas VEGF mRNA in the retina remained con-
stant, VEGF expression was increased as early as 2 weeks after
the onset of diabetes. Increases in expression of 4E-BP1 protein
mirrored those of VEGF and expression of 4E-BP1 mRNA was
unchanged. Similar results were observed after 10 h of exposure
of cells in culture to hyperglycemic conditions. Importantly, the
diabetes-induced increase in VEGF expression was not observed
in mice deﬁcient in 4E-BP1 and 4E-BP2, nor in MEFs lacking the
two proteins.
CONCLUSIONS—Hyperglycemia induces VEGF expression
through cap-independent mRNA translation mediated by in-
creased expression of 4E-BP1. Because the VEGF mRNA con-
tains two internal ribosome entry sites, the increased expression
is likely a consequence of ribosome loading at these sites. These
ﬁndings provide new insights into potential targets for treatment
of diabetic retinopathy. Diabetes 59:2107–2116, 2010
D
iabetic retinopathy is the leading cause of ac-
quired blindness among U.S. citizens under the
age of 65, affecting 5.3 million people, or 2.5% of
the population (1). Diabetic retinopathy in-
cludes both a nonproliferative stage, characterized by
vascular tortuosities, macular edema, microaneurysms
and lipid exudates, and a proliferative stage, characterized
by vascular angiogenesis and potentially severe hemor-
rhages. Examination of vitreous ﬂuid from the eyes of
patients with proliferative diabetic retinopathy demon-
strates an increase in vascular endothelial growth factor
(VEGF) (2–6). Similarly, an increase in VEGF has been
observed in the retina of animal models of diabetes and
ischemia. Because VEGF can promote both vascular per-
meability and angiogenesis, studies on the mechanisms of
diabetes-induced VEGF expression and the effect of VEGF
on retinal vascular function have been areas of intense
study. Changes in glycemia, advanced glycation end prod-
ucts, and localized regions of hypoxia have all been
proposed as mediating an increase in VEGF expression.
Moreover, overexpression of functional VEGF in normal
tissue results in vascular changes similar to those seen in
diabetic retinopathy (7,8). In contrast, inhibition of VEGF
function in the retina by VEGF-neutralizing agents such as
anti-VEGF antibodies (9), overexpression of dominant
negative or chimeric Flt-1/VEGF receptors (10,11), or
inhibition of receptor tyrosine kinases (12) has been
shown to attenuate the abnormal vascular changes asso-
ciated with the disease.
Expression of VEGF is regulated through multiple tran-
scriptional and posttranscriptional mechanisms. Oxygen
tension controls VEGF gene expression through the tran-
scription factor, hypoxia-inducible factor-1 (HIF-1)
(13). During periods of low oxygen tension, for example,
ischemia, HIF-1 is stabilized by interaction with HIF-1,
preventing its proteasome-mediated degradation, as well
as promoting enhanced transcription of speciﬁc genes,
such as VEGF (11,14). The architecture of the VEGF
mRNA 5-untranslated region (UTR) also contributes to
regulation of VEGF expression through translational con-
trol mechanisms. The VEGF mRNA 5-UTR is longer than
average and contains stretches of stable G–C pairing and
areas of complementarity that act to repress translation of
the coding region under normal physiological conditions.
Translation of such mRNAs is thought to occur through a
mechanism that does not require ribosome loading at the
5-m
7GTP cap structure (15). The VEGF message contains
two putative internal ribosome entry sites that allow for
cap-independent translation under conditions of global
translation repression (16,17).
The selection of mRNAs for translation is regulated in
part by the mRNA cap-binding complex, eIF4F, which is
composed of eIF4E, eIF4G, and eIF4A. This complex
serves as an intermediate between the m
7GTP cap and the
40S ribosomal subunit and is required for cap-dependent
binding of mRNA to the ribosome. Assembly of the eIF4F
complex is regulated by a class of eIF4E-binding proteins
(4E-BPs) that inhibit translation by sequestration of eIF4E
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identiﬁed (4E-BP1, -BP2, and -BP3), and, although each is
encoded by a separate gene, their protein sequences are
highly conserved, especially in the region containing the
eIF4E binding domain. In contrast to 4E-BP1 and -BP2,
which are expressed in a variety of tissues, the distribution
of 4E-BP3 is restricted. In the hypophosphorylated state,
4E-BPs compete with eIF4G for binding to eIF4E and
prevent eIF4F complex assembly (19,20), leading to a
decrease in cap-dependent, and a simultaneous increase in
cap-independent, mRNA translation. When phosphory-
lated by the mammalian target of rapamycin complex 1,
4E-BP releases from eIF4E, allowing it to assemble into
the eIF4F complex.
In the present study, we show that VEGF expression in
the retina is increased at early time points in three
different animal models of type 1 diabetes. The increase
occurs despite unchanged expression of VEGF mRNA and
in the absence of a change in HIF-1 expression, suggest-
ing that it is independent of transcriptional regulation and
is likely a result of increased translation of the VEGF
mRNA. 4E-BP1 protein content in the retina of diabetic
animals is also increased in the absence of a change in its
mRNA abundance. Increased 4E-BP1 expression leads to
sequestration of eIF4E, resulting in increased VEGF
mRNA translation. This conclusion is supported by the
observation that the effect is not observed in mice lacking
4E-BP1 and 4E-BP2. These diabetes-induced effects are
likely a consequence of hyperglycemia, because in three
different cell lines, hyperglycemic conditions promote
increased expression of both 4E-BP1 and VEGF, indepen-
dent of changes in the abundance of their mRNAs. More-
over, similar to what is observed in the retina of diabetic
mice, the hyperglycemia-induced increase in VEGF ex-
pression in mouse embryo ﬁbroblasts (MEFs) requires
4E-BP1. Overall, the results indicate that diabetes-induced
hyperglycemia mediates increased expression of 4E-BP1,
leading to enhanced translation of the VEGF mRNA.
RESEARCH DESIGN AND METHODS
Male Sprague-Dawley rats (120–180 g) were housed in The Pennsylvania State
University College of Medicine Animal Facility in accordance with Institu-
tional Animal Care and Use Committee (IACUC) guidelines. Type 1 diabetes
was induced in rats by a single intraperitoneal injection of streptozotocin
(STZ), as previously described (21). Rats exhibiting blood glucose levels
above 250 mg/dl, measured 24 h after drug administration, were considered
diabetic. Average blood glucose values for the animal models used herein are
shown in supplementary Fig. 1 in the online appendix available at
http://diabetes.diabetesjournals.org/cgi/content/full/db10-0148/DC1.
Male C57BL/6J Ins2
Akita heterozygous mice were bred in The Pennsylvania
State University College of Medicine Juvenile Diabetes Research Foundation
Diabetic Retinopathy Center Animal Core, in accordance with IACUC guide-
lines. At 4.5 weeks of age, mice were genotyped and tested for a diabetic
phenotype, that is, a blood glucose level exceeding 250 mg/dl. Wild-type
littermates were used as controls (22).
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FIG. 1. VEGF expression is increased in the retina of diabetic rats in
the absence of changes in VEGF mRNA. A: Western blot analysis of
VEGF expression. VEGF expression was analyzed in retinal samples
from 13 control and 14 diabetic rats at 1 week, 12 control and 14
diabetic rats at 2 weeks, 12 control and 12 diabetic rats at 4 weeks, 13
control and 13 diabetic rats at 6 weeks, and 5 control and 7 diabetic
rats at 12 weeks as described in RESEARCH DESIGN AND METHODS. The
antibody used in these studies recognizes the 121, 165, and 189 splice
variants of VEGF. The molecular weights of the two bands detected by
Western blot correspond to the 165 and 189 splice variants. VEGF-A
binds to both the VEGF receptor 1 (VEGFR1) and VEGFR2. Activation
of the receptors leads to increased vascular permeability and upregu-
lated angiogenesis. Values represent the mean expressed as a percent-
age of the control value  SEM; control (white bars) and diabetic
(black bars) animals. B: Quantitative RT-PCR of VEGF mRNA. Total
RNA was extracted from the retina of 6 control and 9 diabetic rats at
4 weeks, 3 control and 6 diabetic rats at 6 weeks, and 10 control and 10
diabetic rats at 12 weeks as described under RESEARCH DESIGN AND
METHODS. Values represent the mean expressed as a percentage of an
internal -actin control  SEM. C: Western blot analysis of HIF-1
protein expression. HIF-1 protein expression was analyzed in retinal
samples from 5–6 control and 4–5 diabetic rats at each time point as
described in RESEARCH DESIGN AND METHODS. Values represent the mean
expressed as a percentage of the control value  SEM. *P < 0.05 versus
corresponding control value.
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previously (23). At 4 weeks of age, type 1 diabetes was induced according to
the AMDCC “Low-Dose Streptozotocin Induction Protocol (Mouse)” (24).
Mice with blood-glucose levels exceeding 250 mg/dl each week were consid-
ered diabetic, and those that did not meet this threshold were excluded from
the study.
Cell culture. TR-MUL [kindly provided by Dr. Ken-ichi Hosoya (Toyama
Medical and Pharmaceutical University)] and Moorﬁelds/Institute of Ophthal-
mology-Mu ¨ller 1 [kindly provided by Dr. G. Astrid Limb (University College of
London)] retinal Mu ¨ller cells, and wild-type and Eif4ebp1;Eif4ebp2 double
knockout MEFs (23) were maintained in Dulbecco’s modiﬁed Eagle’s medium
containing 5.6 mmol/l glucose and 2% heat-inactivated FBS and grown to
subconﬂuence before seeding. Cells were maintained at either 37°C (MIO-M1
and MEFs) or 33°C (TR-MUL), in a humidiﬁed, 5% CO2 atmosphere. TR-MUL
and MIO-M1 cells (500,000) were seeded into 6-well dishes, and MEF cells
(20,000) were seeded into 12-well dishes and grown to 75% conﬂuence.
Culture medium was aspirated, cells were washed with sterile PBS, and
experimental medium was added. For studies of the effects of hyperglycemic
conditions, cells were either replenished with medium containing 5.6 mmol/l
glucose and 25 mmol/l mannitol (hereafter referred to as control medium) or
25 mmol/l glucose and 10% heat-inactivated FBS (hereafter referred to as
high-glucose medium) for 10 h (unless otherwise indicated).
Protein analysis. At the indicated time points, the retina was isolated,
ﬂash-frozen in liquid nitrogen, and later sonicated in 500 l of extraction
buffer (25) supplemented with inhibitors [microcystin, sodium vanadate,
benzamidine, and protease inhibitor cocktail (Sigma-Aldrich)]. The homoge-
nate was centrifuged at 12,000 rpm for 10 min at 4°C, and the supernatant was
collected, a fraction of which was added to 1 Laemmli buffer and boiled for
5 min. For Western blot analysis of these samples, 60 g of protein was loaded
per lane. In studies using cells in culture, medium was collected for VEGF
analysis, and cells were washed in sterile PBS, then scraped in 200 l of either
1 Laemmli buffer, immunoprecipitation homogenization buffer (20 mmol/l
HEPES, 2 mmol/l EGTA, 50 mmol/l NaF, 100 mmol/l KCl, 0.2 mmol/l EDTA, 50
mmol/l -glycerophosphate, pH 7.4, 1 mmol/l benzamidine, 0.5 mmol/l sodium
vanadate, 1 mol/l microcystin, and 15 l/ml protease inhibitor cocktail), or
Lambda phosphatase buffer (26), supplemented with inhibitors (except mi-
crocystin and sodium vanadate). For Western blot analysis of these samples,
30 g of protein was loaded per lane. Protein was separated by SDS-PAGE on
15%, 4–15%, or 4–20% Criterion gels (Bio-Rad Laboratories) and transferred to
a polyvinylidene ﬂuoride membrane. The membrane was blocked in 5% milk
in Tris-buffered saline Tween-20, washed, and then incubated overnight at 4°C
with primary antibody. The source of polyclonal antibodies, and the dilutions
used in Western blot analysis, are presented in supplementary Table 1,
available in an online appendix. Monoclonal antibodies to the -subunit of
eIF2, eIF4E, and eIF4G were prepared in our laboratory as described
previously (27–29). The membranes were incubated with horseradish perox-
idase-conjugated secondary antibody, washed, incubated for1ha ta1:10,000
dilution, and then developed using enhanced chemiluminescence. Quantita-
tion was performed using a GeneGnome HR imaging system with GeneTools
software (SynGene).
For analysis of VEGF production in cells in culture, media was collected
from control and treated cells and subjected to VEGF ELISA (Qiagen)
following the manufacturer’s protocol. VEGF concentration was normalized
to total cellular protein content.
Lambda phosphatase treatment. The retinas and harvested cells were
sonicated in 500 and 200 l, respectively, of Lambda phosphatase buffer (26),
supplemented with benzamidine and protease inhibitor cocktail, and the
homogenate was combined with 4 l (1,600 units) of Lambda phosphatase and
incubated for1ha t37°C. The sample was centrifuged at 1,000 g for 3 min, and
the supernatant was boiled for 3 min, combined with 2 Laemmli buffer,
boiled again for 5 min, and subjected to Western blot analysis.
Analysis of eIF4E:4E-BP interaction. BioMag goat-anti-mouse IgG mag-
netic beads (BioClone Inc.) (1.5 ml/sample) were washed thrice in low salt
buffer (20 mmol/l Tris-HCl, pH 7.4, 5 mmol/l EDTA, 150 mmol/l NaCl, 0.5%
Triton X-100, 0.1% -mercaptoethanol) and then resuspended in 1/5 of the
original volume in low salt buffer. Beads were combined with 175 l PBS, 12.5
l Triton X-100, and 4 g monoclonal anti-eIF4E antibody (per sample) and
incubated on an orbital rocker overnight at 4°C. On the day of the study, the
retinas were homogenized using a Dounce homogenizer in 500 l of eIF4E
homogenization buffer (20 mmol/l HEPES, 2 mmol/l EGTA, 50 mmol/l sodium
ﬂuoride, 100 mmol/l potassium chloride, 0.2 mmol/l EDTA, 50 mmol/l -glyc-
erophosphate, pH 7.4) plus inhibitors. Alternatively, cells in culture were
harvested in immunoprecipitation buffer containing 2.5% Triton X-100 and
0.25% deoxycholate. Retinal or cell homogenate was added to 1 ml or 200 l,
respectively, of BioMag bead-bound eIF4E antibody and incubated for1ha t
4°C. The beads were washed, resuspended in 1 Laemmli buffer, and boiled
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FIG. 2. The relative phosphorylation of a number of biomarkers of mRNA
translational control is unchanged in the retina after induction of diabe-
tes. Samples from retinal homogenates prepared as described in RESEARCH
DESIGN AND METHODS were assessed for the relative phosphorylation of (A)
eIF2 on Ser51, (B) eIF4G on Ser1108, and (C) eIF4E on Ser209. Values
for phosphorylation status were normalized to the amount of the respec-
tive total protein. Values represent the mean  SEM of at least three
independent sets of animals at each time point (n  2–4 within each set),
except that the control value for eIF2 at 6 weeks represents two
animals. Control (white bars) and diabetic (black bars) animals.
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diabetes.diabetesjournals.org DIABETES, VOL. 59, SEPTEMBER 2010 2109for 5 min. After the beads were removed, 20 l of sample was loaded onto a
4–15% Criterion gel and subjected to Western blot analysis.
Quantitative real-time PCR. RNA was isolated from retinas after using
TriZol (Invitrogen) as per the manufacturer’s protocol. Total RNA, at least 500
ng, was reverse transcribed using an ABI High Capacity cDNA Reverse
Transcription Kit according to the manufacturer’s protocol. For quantitation
of mRNA, qRT-PCR was performed using Taqman RT-PCR assay. The se-
quence of the Taqman (R) Gene Expression Assay primers used herein are
presented in supplementary Table 2, available in an online appendix.
For cell culture studies, qRT-PCR was performed using QuantiTech SYBR
Green PCR Kit (Qiagen) and the following QuantiTech Primer Assay kits
(Qiagen) following the manufacturer’s protocol: -actin (Rn_Actb_1_SG Quanti-
Tect Primer Assay NM_031144), VEGFA (Rn_RGD:619991_1_SG QuantiTect
Primer Assay NM_001110335), and 4E-BP1 (Rn_Eif4ebp1_1_SG QuantiTect
Primer Assay NM_053857).
Statistical analysis. Results from the retina of diabetic animals were
compared by ANOVA or Student t test to those from the retina of their
nondiabetic counterparts using Prism 4 (GraphPad Software, Inc.). Where
appropriate, data were log-transformed for normality. Data from untreated
control cells were compared either by ANOVA or Student t test, whichever
appropriate, with that from their treated counterparts using Prism 4. The data
are presented as mean  SEM; P  0.05 was considered statistically
signiﬁcant.
RESULTS
Type 1 diabetes results in increased VEGF protein,
but not mRNA, expression in the retina. Alterations in
VEGF expression were assessed by Western blot analysis
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FIG. 3. Enhanced association of 4E-BP1 with eIF4E in the retina of diabetic rats is a result of decreased phosphorylation and increased expression
of 4E-BP1. A: eIF4E immunoprecipitation. eIF4E immunoprecipitation was carried out as described in RESEARCH DESIGN AND METHODS. Twenty L
of sample was loaded per well. The amount of 4E-BP1 and 4E-BP2 present in the immunoprecipitate was normalized to eIF4E and displayed as
a percentage of the control mean  SEM (n  8); control (white bars) and diabetic (black bars) animals. B: Western blot analysis of 4E-BP1
phosphorylation. 4E-BP1 phosphorylation on T37/46 was normalized to total 4E-BP1 measured from 12 control and 12 diabetic rat retinal extracts
4 weeks after the induction of diabetes; values are displayed as a percentage of the control mean  SEM. C: Western blot analysis of 4E-BP1
expression. Sixty g of protein was loaded per lane. Representative blots are shown. D: Quantitative RT-PCR of 4E-BP1 mRNA. Retinal RNA was
extracted as described in RESEARCH DESIGN AND METHODS from 6 control and 9 diabetic rats at 4 weeks, 3 control and 6 diabetic rats at 6 weeks, and
10 control and 10 diabetic rats at 12 weeks. Values represent the mean expressed as a percentage of internal -actin control  SEM. *P < 0.05,
**P < 0.01, ***P < 0.001 versus corresponding control value.
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induced type 1 diabetic rats at various times after drug
administration. Whereas VEGF expression was increased
signiﬁcantly in the retina of diabetic compared with con-
trol rats at 2, 4, and 6 weeks (Fig. 1A), the relative
abundance of VEGF mRNA remained constant (Fig. 1B).
In addition to constant expression of VEGF mRNA, expres-
sion of the transcription factor, HIF-1, did not differ among
the groups (Fig. 1C), suggesting that the mechanism for
increased VEGF expression was posttranscriptional.
Phosphorylation of eIF2, eIF4G, and eIF4E is the
same in the retina of diabetic compared with control
rats. Because the expression of the VEGF mRNA did not
change over the time course used above, mechanisms
involved in the regulation of mRNA translation were
explored that might explain increased expression of the
protein. Such mechanisms include changes in phosphory-
lation of eIF4E, eIF4G, and the -subunit of eIF2. There-
fore, the phosphorylation state of each of these proteins
was assessed at various times after STZ treatment. No
signiﬁcant difference in phosphorylation of eIF2 on Ser51
(Fig. 2A), eIF4G on Ser1108 (Fig. 2B), or eIF4E on Ser209
(Fig. 2C) was observed in the retina of diabetic compared
with control rats at 1, 2, 4, or 6 weeks of diabetes.
Increased association of 4E-BP1 with eIF4E is a
result of increased expression of 4E-BP1 in the ret-
ina of diabetic rats. Another mechanism through which
the selection of mRNAs for translation is regulated in-
volves the sequestration of eIF4E by 4E-BP1 (30). There-
fore, 4E-BP1 association with eIF4E was assessed, and,
as shown in Fig. 3A, a signiﬁcant increase in 4E-BP1
associated with eIF4E was detected in the retina of
diabetic compared with control rats, with no change in
the amount of 4E-BP2 bound to eIF4E (Fig. 3A). The
increased association was attributed to both a reduction
in the relative phosphorylation of 4E-BP1 on T37/46, a
key regulatory phosphorylation site (Fig. 3B), and to
increased expression of 4E-BP1 (Fig. 3C). The time
course of changes in 4E-BP1 expression paralleled that
observed for VEGF (Fig. 1A). 4E-BP1 mRNA expression
was unchanged (Fig. 3D).
VEGF and 4E-BP1 expression are coordinated in a
genetic model of type 1 diabetes. The Ins2
Akita mutation
is a single amino acid substitution (C96Y) in the insulin 2
gene that disrupts disulﬁde bond formation between the A
and B chains, resulting in misfolding of proinsulin. The
accumulation of misfolded protein leads to ER stress and,
ultimately, -cell apoptosis and development of hypoinsu-
linemia and hyperglycemia (22). These mice have been
used in recent studies to investigate diabetic complica-
tions in light of the similar disease progression and char-
acteristics to that of the established STZ-induced model of
type 1 diabetes, including increased retinal vascular per-
meability and elevated apoptosis (22). Thus, to further
evaluate the correlation between increased VEGF and
4E-BP1 expression observed in the STZ-induced model of
type 1 diabetes in the rat, retinas were harvested from
Ins2
Akita mice at various time points and analyzed for
VEGF and 4E-BP1 protein and mRNA expression. The
time course for increased VEGF expression in the Ins2
Akita
mice was delayed compared with that of the STZ-induced
diabetic rat, but the elevated expression of VEGF and
4E-BP1 protein (Fig. 4A and B, respectively) were similar
in both models of diabetes.
Ablation of 4E-BP1 prevents the diabetes-induced
increase in VEGF expression. If an increase in 4E-BP1
availability is necessary for the increased expression of
VEGF, then the absence of 4E-BP1 would be expected to
prevent the diabetes-induced change in VEGF expression.
To test this hypothesis, retinas from control and STZ-
induced diabetic, wild-type, and 4E-BP1 and 4E-BP2 dou-
ble knockout (Eif4ebp1;Eif4ebp2) mice were analyzed.
While retinal 4E-BP1 protein was detected in Eif4ebp1;
Eif4ebp2 wild-type mice, the protein was undetectable in
the retinal extracts from Eif4ebp1;Eif4ebp2 double knock-
out mice, conﬁrming lack of 4E-BP1 expression in these
mice (Fig. 5A). After 5 weeks of STZ-induced diabetes,
VEGF expression was signiﬁcantly higher in the retina of
the diabetic compared with the control Eif4ebp1;Eif4ebp2
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expression. Sixty g of protein was loaded per lane. Values represent
the mean expressed as a percentage of control samples  SEM. Data
are representative of retinas from seven wild-type (WT) and four
Ins2
Akita diabetic (Ins) mice at 3 months, and three WT and three
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corresponding control value.
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VEGF expression in the retina of Eif4ebp1;Eif4ebp2 dou-
ble knockout mice (Fig. 5B), despite severe hyperglycemia
(supplementary Fig. 1C). This result demonstrates that an
increase in 4E-BP1 availability is necessary for the diabe-
tes-induced increase in VEGF expression.
Hyperglycemic conditions induce 4E-BP1 expression
and association with eIF4E in retinal Mu ¨ller cells in
culture. To assess whether hyperglycemic conditions
contribute to the increase in 4E-BP1 and VEGF expression
in the retina of diabetic animals, TR-MUL Mu ¨ller cells were
incubated in either control or high-glucose medium for
various times. 4E-BP1 expression was signiﬁcantly in-
creased 4 h after exposure to high glucose and continued
to be elevated through 18 h of treatment (Fig. 6A). As the
maximal increase in 4E-BP1 occurred at 10 h of treat-
ment, this time point was selected for further studies. An
increase in 4E-BP1 expression was also observed in the
human Mu ¨ller cell line, MIO-M1 (Fig. 6B), in response to
incubation in high-glucose medium, demonstrating that
the effect of hyperglycemic conditions was not speciﬁc for
TR-MUL cells. Although 4E-BP1 protein content was sig-
niﬁcantly increased at all time points, the expression of
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tionally, hyperglycemic conditions caused a decrease in
the relative phosphorylation of 4E-BP1 on T37/46 (Fig.
7B). Increased expression and decreased phosphorylation
resulted in a signiﬁcant increase in the amount of 4E-BP1
bound to eIF4E, as measured in eIF4E immunoprecipi-
tates (Fig. 7C). Thus, similar to the effect observed in the
retina of diabetic rodents, 4E-BP1 expression was in-
creased in response to hyperglycemic conditions in Mu ¨ller
cells in culture. The increased VEGF expression in Mu ¨ller
cells is consistent with the immunolocalization of VEGF in
human eyes of patients with diabetes (31).
Induction of VEGF secretion under hyperglycemic
conditions requires 4E-BP1 expression. To determine
whether hyperglycemic conditions resulted in the induc-
tion of VEGF, medium was collected for measurement of
VEGF secretion by ELISA. After 10 h of high-glucose
treatment, the VEGF concentration in the cell culture
medium was signiﬁcantly elevated for VEGFA content
(Fig. 8A). However, there was no change in the expression
of VEGFA mRNA in the cell lysates (Fig. 8B), suggesting a
posttranscriptional mechanism for the stimulated produc-
tion of VEGF. VEGF secretion was also stimulated in
MIO-M1 cells incubated in the high-glucose medium com-
pared with the control medium (Fig. 8C).
To conﬁrm the dependence of VEGF induction on
4E-BP1 expression, wild-type and Eif4ebp1;Eif4ebp2 dou-
ble knockout MEFs were exposed to either control or
high-glucose medium for 10 h. Expression of 4E-BP1 and
4E-BP2 was undetectable in the double knockout cells
(data not shown). As observed in Mu ¨ller cells, 4E-BP1
expression was increased in wild-type MEFs during hyper-
glycemic conditions (data not shown), and this was asso-
ciated with a 2.5-fold stimulation of VEGF secretion into
the medium (Fig. 8D). Secretion of VEGF from double
knockout MEFs, on the other hand, was not stimulated
under hyperglycemic conditions, conﬁrming the require-
ment for increased 4E-BP1 expression (Fig. 8D).
DISCUSSION
In the present study, VEGF expression was increased,
without a change in VEGF mRNA expression, in the retina
of three animal models of type 1 diabetes: STZ-induced
diabetic rats and mice and Ins2
Akita mice. An increase in
VEGF expression also occurred in the absence of changes
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FIG. 7. Relative phosphorylation of 4E-BP1 on T37/46 is reduced
under hyperglycemic conditions, leading to enhanced association
with eIF4E. A: Quantitative RT-PCR of 4E-BP1 mRNA. TR-MUL
cells were exposed to control medium (white bar) or high-glucose
medium (black bar) for 10 h followed by RNA extraction as
described in RESEARCH DESIGN AND METHODS. Values represent the
mean of 4E-BP1 mRNA expression normalized to an internal
-actin control and are expressed as a percentage of control 
SEM of 5 or 6 dishes of cells per condition. B: Western blot analysis
of 4E-BP1 phosphorylation on T37/46. MIO-M1 cells were exposed
to control or high-glucose medium and 30 g of protein were
subjected to Western blot analysis for 4E-BP1 T37/46 phosphor-
ylation. Values represent the mean expressed as a percentage of
the control  SEM of 5 or 6 dishes of cells per condition. C:
Analysis of 4E-BP1:eIF4E association. Lysates from eIF4E im-
munoprecipitates were subjected to Western blot analysis for
the coimmunoprecipitation of 4E-BP1 from cells exposed to
control or high-glucose medium. Values represent the mean
expressed as a percentage of the control  SEM of 6 dishes of
cells per condition. Representative blots are shown as an inset.
*P < 0.05 versus corresponding control value.
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lines as well as in MEFs exposed to hyperglycemic condi-
tions. These ﬁndings suggest that VEGF expression is
regulated in a manner that is independent of changes in
expression of the message. Although other groups have
reported an increase in VEGF mRNA expression in the
retina of diabetic animals (32,33), under the conditions
used in the present study, no difference was detected.
The results presented herein indicate that 4E-BP1/2 is
necessary for the increased expression of VEGF in the
retina during diabetes, as the absence of the binding
proteins prevents the change. 4E-BP1/2 is also required for
the increase in VEGF expression in MEFs maintained in
culture under hyperglycemic conditions, as VEGF expres-
sion did not increase in 4E-BP1/2 double knockout MEFs
exposed to hyperglycemic conditions. In both the retina
and in cells in culture, the increase in 4E-BP1 expression
led to enhanced binding to eIF4E. Under conditions pro-
moting eIF4E sequestration into the eIF4E4E-BP1 com-
plex, there is a switch to cap-independent translation,
making mRNAs that are normally inefﬁciently translated,
such as the one encoding VEGF, more competitive for
translation (33–37). While further studies are required to
identify the exact mechanism of 4E-BP1/2-induced regula-
tion of VEGF mRNA translation, it is likely that increased
VEGF internal ribosome entry sites utilization accounts
for the enhanced expression of the protein.
Increased 4E-BP1 protein content in the absence of
changes in 4E-BP1 mRNA expression suggests regulation
at the posttranscriptional level in both the retina of
diabetic animals and in cells in culture exposed to hyper-
glycemic conditions. However, unlike the VEGF mRNA,
the mRNAs encoding mouse and human 4E-BP1 have
relatively short 5-UTRs that lack signiﬁcant secondary
structure in prediction models. Moreover, the 5-UTR of
the 4E-BP1 mRNA lacks other regulatory sequences that
might be involved in translational regulation, such as open
reading frames or terminal oligopyrimidine tracts. Al-
though other translational regulatory mechanisms such as
microRNAs cannot be discounted, changes in the rate of
degradation may contribute to alterations in 4E-BP1 ex-
pression. In this regard, evidence for proteasome-depen-
dent degradation of 4E-BP1 has been shown by
accumulation of the protein after proteasome inhibition
(34) and by ubiquitin immunoprecipitation (35). In the
present study, increased binding of 4E-BP1 to eIF4E in the
retina of diabetic rats is consistent with possible de-
creased ubiquitination of 4E-BP1, because previous stud-
ies (35) have shown inefﬁcient binding of ubiquitinated
4E-BP1 to eIF4E. Whether or not 4E-BP1 degradation is
decreased in the retina of diabetic rodents will be explored
in future studies.
A role for 4E-BP1 in regulating VEGF mRNA translation
has also been reported in immortalized proximal tubular
epithelial (MCT) cells (36). Treatment of MCT cells with
angiotensin II promotes increased phosphorylation of 4E-
BP1 and recruitment of VEGF mRNA into polysomes.
Moreover, incubation in medium containing 30 mmol/l
instead of 5 mmol/l glucose leads to increased synthesis of
angiotensinogen, a precursor of angiotensin II, as well as
VEGF (37). Together these data suggest that elevations in
glucose concentration may promote VEGF mRNA transla-
tion by increasing expression of angiotensin II, and subse-
quently 4E-BP1 phosphorylation. Angiotensin II has also
been implicated in changes in VEGF expression in the
retina of diabetic rodents (38–40). However, in the animal
models of diabetes used in those studies, VEGF mRNA
expression was increased, a ﬁnding not observed in the
present study. Further, in the present study, the 4E-BP1
content increased causing a relative decrease in the
amount of phosphorylated 4E-BP1, suggesting a distinct
mechanism from that observed in MCT cells. Whether or
not changes in angiotensin II expression might be involved
in the increase in VEGF expression observed in the models
of diabetes used herein is unknown.
In the present study, VEGF expression was increased in
the retina of diabetic compared with control rats as early
as 2 weeks of STZ-induced type 1 diabetes. The elevated
expression was sustained for at least 6 weeks but returned
to basal levels by 12 weeks. Many studies have docu-
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FIG. 8. Hyperglycemic conditions stimulate secretion of VEGF in retinal Mu ¨ller cells, but not in Eif4ebp1;Eif4ebp2 double knockout (DKO) MEFs.
A: Analysis of VEGF secretion. Medium was collected from TR-MUL cells exposed to control medium (white bar) or high-glucose medium (black
bar) and subjected to ELISA analysis of VEGFA concentration. VEGF was normalized to protein content in the cell lysates. Values represent the
mean expressed as a percentage of the control  SEM of 6 dishes of cells per condition. B: Quantitative RT-PCR of VEGF mRNA. RNA was
extracted from TR-MUL cells exposed to control or high-glucose medium followed by RNA isolation as described in RESEARCH DESIGN AND METHODS.
Values represent the mean of 4E-BP1 mRNA expression normalized to an internal -actin mRNA control and are expressed as a percentage of
control  SEM of 6 dishes of cells per condition. C: Analysis of VEGF secretion in the human Mu ¨ller cell line, MIO-M1. Medium was collected from
TR-MUL cells exposed to control or high-glucose medium and subjected to ELISA for measurement of VEGFA concentration as described above.
Values represent the mean expressed as a percentage of the control  SEM of 6 dishes of cells per condition. D: Analysis of VEGF secretion.
Medium was collected from Eif4ebp1;Eif4ebp2 WT and DKO MEFs exposed to control or high-glucose medium and subjected to ELISA for VEGFA
concentration. Values represent the mean expressed as a percentage of the control  SEM of 9 dishes of cells of WT cells per condition and 6
dishes of double-knockout cells per condition. *P < 0.001, †P < 0.01 when compared with DKO cells maintained in control medium.
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betic retinopathy, such as vascular permeability (41),
appearance of acellular capillaries (42), and endothelial
apoptosis (43), occur after prolonged periods, for exam-
ple, 3–8 months, of diabetes in rodents, while other
studies have observed vascular changes by 1 week (44).
One study (33) reported blood–retinal barrier breakdown
in response to a near twofold increase in VEGF expression
after only 8 days of diabetes. The increase in permeability
was entirely prevented by treatment with a chimeric VEGF
receptor (33). Therefore, increased VEGF expression has
been observed in multiple animal models, but the time of
increase varies with the model and method of diabetes
induction as was observed within this study comparing
VEGF expression in rat and mouse models of type 1
diabetes.
In the present study, three rodent models of type 1
diabetes yielded similar results in increased expression of
VEGF and 4E-BP1. Together, the evidence from these
studies strongly suggests that 4E-BP1 is a key modulator
of translational control of VEGF expression in the retina
during diabetes. Further details about the regulation of
VEGF expression may lead to novel therapies to control
abnormal vascular permeability and angiogenesis in dia-
betic retinopathy.
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